Abstract
The objective of this study was to analyse the market share of generic vs originator selective serotonin re-uptake inhibitors (SSRIs), and also compare market share of different SSRIs in the private health care sector in South Africa, over a period of 4 years. This was a retrospective, descriptive study that measured generic market volume as a percentage of the total private SSRI market volume. Retail private sector sales data for six SSRIs available in the private sector in South Africa was evaluated. Sales data were obtained from various stages in the pharmaceutical supply chain, June 2009 - May 2013. Generics constituted 86% and originators 14% of the private sector market volume of SSRIs. The share of the market volume of generic medicines increased by 29.93% over this 4-year period, while an overall increase of 27.86% in the ratio of generics to originators was observed. In line with policies, generic SSRIs hold a larger volume of the market in the private sector in South Africa.
Highlights
Depression is a debilitating disorder in which patients have a low self-esteem and feel helpless, sad, and guilty.[1]
The share of the market volume of generic medicines increased by 29.93% over this 45-year period, while an overall increase of 27.86% in the ratio of generics to originators was observed
Results from this study show an increase in the market volume of generic selective serotonin re-uptake inhibitors (SSRIs), while there is no significant change to the market volume of originator SSRIs
Summary
Depression is a debilitating disorder in which patients have a low self-esteem and feel helpless, sad, and guilty.[1] According to the World Health Organisation, depression is affecting about 350 million people worldwide, the demand for curbing and treating this mental health disorder is a global challenge. A recent South African study reported that depression was the most common diagnosis, being present in nearly two thirds (63.9%) of non-fatal suicidal patients seen in a large academic hospital.[1]. Depression is amongst the most commonly occurring chronic illnesses worldwide, and cost of illness research. According to the FDA, generic medicine is identical, or bioequivalent, to an originator in terms of dosage form, safety, strength, route of administration, quality, performance characteristics and intended use.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
